1. Home
  2. GIXI vs BIAF Comparison

GIXI vs BIAF Comparison

Compare GIXI & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gix Internet Ltd. Ordinary Shares

GIXI

Gix Internet Ltd. Ordinary Shares

N/A

Current Price

$4.05

Market Cap

9.7M

Sector

Technology

ML Signal

N/A

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

HOLD

Current Price

$3.17

Market Cap

9.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GIXI
BIAF
Founded
1978
2014
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.7M
9.2M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
GIXI
BIAF
Price
$4.05
$3.17
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.3M
★ 1.6M
Earning Date
11-30-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $7,900,000.00
Revenue This Year
N/A
$18.58
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 14.49
52 Week Low
$3.56
$0.37
52 Week High
$8.34
$21.52

Technical Indicators

Market Signals
Indicator
GIXI
BIAF
Relative Strength Index (RSI) 39.34 35.32
Support Level $3.79 $1.39
Resistance Level $8.34 $5.94
Average True Range (ATR) 0.72 0.73
MACD 0.03 -0.23
Stochastic Oscillator 7.53 0.56

Price Performance

Historical Comparison
GIXI
BIAF

About GIXI Gix Internet Ltd. Ordinary Shares

Gix Internet Ltd provides infrastructure for managing and authorizing autonomous systems, including autonomous mobile robots (AMRs), automated guided vehicles (AGVs), humanoid robots, robotaxis, shuttles, drones, and human workforces. The company's platform provides: mission generation and orchestration across mixed-fleet environments; real-time authorization and policy-gate enforcement for regulatory compliance; and cryptographically signed records of authorized actions for regulatory compliance.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

Share on Social Networks: